Traub Capital Management LLC Takes Position in Pfizer Inc. $PFE

Traub Capital Management LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 26,068 shares of the biopharmaceutical company’s stock, valued at approximately $632,000.

Several other large investors have also bought and sold shares of PFE. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the first quarter worth about $27,000. Curio Wealth LLC boosted its stake in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter valued at approximately $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer during the 2nd quarter worth approximately $29,000. Finally, WPG Advisers LLC bought a new position in Pfizer in the 1st quarter valued at approximately $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $25.45 on Wednesday. The stock’s 50 day moving average is $24.82 and its 200 day moving average is $24.46. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The firm has a market cap of $144.70 billion, a P/E ratio of 13.54, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s payout ratio is presently 100.00%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PFE. The Goldman Sachs Group reiterated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.